{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-005188","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.951682+00:00","generated_at":"2026-06-17T07:35:58.478855+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bio-Path reports FY2022 net loss of $13.9M ($1.91/share); cash drops to $10.4M","bullets":["Net loss $13.9M ($1.91 per share) vs $10.4M ($1.55) in 2021; R&D expense rose to $9.2M.","Cash at Dec 31, 2022 was $10.4M, down from $23.8M; operating cash burn of $15.1M.","First patient dosed in Phase 1/1b trial of BP1001-A in solid tumors (ovarian, pancreatic, breast).","Phase 2 prexigebersen AML trial: two cohorts exceeded minimum efficacy; interim analyses expected Q2 2023.","BP1002 Phase 1/1b in relapsed/refractory AML: initial cohort data readout expected Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-005188","json":"https://secwatch.observer/filing/0001558370-23-005188.json","markdown":"https://secwatch.observer/filing/0001558370-23-005188.md","text":"https://secwatch.observer/filing/0001558370-23-005188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023005188/0001558370-23-005188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023005188/bpth-20230331x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:35:58.478855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dd58ac25f04805623a8aebb6504b18ef5ccc2fed","claim":"BIO-PATH HOLDINGS, INC. reported the year ended December 31, 2022 results: net income a net loss of $13.9 million, or $1.91 per share.","evidence_excerpt":"The Company reported a net loss of $13.9 million, or $1.91 per share, for the year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023005188/0001558370-23-005188-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"a net loss of $13.9 million, or $1.91 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}